D-0766-2023 Class III Terminated

Recalled by Teva Pharmaceuticals USA Inc — Parsippany, NJ

FDA drug recall D-0766-2023 was initiated by Teva Pharmaceuticals USA Inc on Apr 27, 2023 and is designated Class III. Reason for recall: Labeling: Incorrect or Missing Package Insert The recall status is terminated (terminated Feb 29, 2024). Affected quantity: 438.

Recall details

Product Type
Drugs
Report Date
May 31, 2023
Initiation Date
Apr 27, 2023
Termination Date
Feb 29, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
438

Product description

Fentanyl Buccal Tablets CII, 100mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834, NDC 51862-634-28

Reason for recall

Labeling: Incorrect or Missing Package Insert

Distribution pattern

US Nationwide

Code information

Lot# 42617828, Exp 06/2023; 100020465, Exp 01/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0766-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0766-2023. Report a data issue: hello@regdatalab.com.